Valbiotis Stock

ALVAL

FR0013254851

Biotechnology & Medical Research

Market Closed - Euronext Paris 11:55:00 2026-08-17 EDT			5-day change	1st Jan Change
0.8560 ^EUR	-0.47%		+5.16%	+23.34%

07-22	Valbiotis Publishes Results of Reverse-It Clinical Study Evaluating Totum 63 in Nature Communications	CI
06-29	Valbiotis Raises EUR10 Million for Commercial Development, Working Capital	MT

Analysts' recommendations: Valbiotis

05-12	Valbiotis shares surge on Asian expansion plans
24-10-30	Valbiotis: Invest Securities reduces its target
23-07-17	Valbiotis: Invest Securities confirms its recommendation
23-05-25	Valbiotis: Oddo BHF raises its target price
23-05-23	Valbiotis: promising study, Invest Sec. raises its target

More recommendations

News in other languages: Valbiotis

07-27	VALBIOTIS SA: Loi sur la prévention cardiovasculaire : Une réponse à un enjeu de santé public majeur Une avancée en pleine cohérence avec la mission de Valbiotis
07-22	VALBIOTIS SA: Les résultats de l’étude clinique REVERSE-IT publiés dans Nature Communications, une reconnaissance scientifique internationale majeure pour l’ingrédient Totum•63
07-22	VALBIOTIS SA: Bilan semestriel du contrat de liquidité.
06-29	Bourse : Ipsen rachète Kartos, Google et Meta se chicanent, Samsung et SK investissent
06-29	Le marché prend une partie de ses bénéfices sur l'IA

More news

Managers and Directors: Valbiotis

Manager	Title	Age	Since
Sebastien Peltier CEO	Chief Executive Officer	-	-
Stanislas Sordet DFI	Director of Finance/CFO	-	2024-02-29
Pascal Sirvent CTO	Chief Tech/Sci/R&D Officer	-	2017-08-31

Director	Title	Age	Since
Laurent Lévy CHM	Chairman	55	2017-02-28
Jean Zetlaoui BRD	Director/Board Member	-	2017-10-25
Agnès Tixier BRD	Director/Board Member	-	2019-03-17

More insiders

VALBIOTIS is a French laboratory specializing in the creation and distribution of dietary supplements scientifically tested to maintain health at every stage of life. Through an innovative approach combining scientific excellence, plant expertise and a wealth of natural ingredients, VALBIOTIS offers a new generation of dietary supplements to support cardio-metabolic balance and well-being, and address everyday health issues such as sleep, fatigue, mood management, immunity and vitality.

Employees

Sector

Biotechnology & Medical Research

Calendar

10-12 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-08-17	€0.8560	-0.47%	93,025
26-08-14	€0.8600	-1.04%	192,468
26-08-13	€0.8690	+5.72%	614,579
26-08-12	€0.8220	-0.24%	74,696
26-08-11	€0.8240	+1.23%	98,504

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.8560EUR

Average target price

1.800EUR

Spread / Average Target

+110.28%

Consensus

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Stock Market
Stocks
ALVAL Stock

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	20.25M 23.46M 19M 17.3M 32.54M 2.24B 32.99M 223M 87.27M 1.12B 88.07M 86.16M 3.74B	P/E 2026 *	-3.72x	P/E 2027 *	-10.7x
Enterprise Value	26.15M 30.29M 24.53M 22.35M 42.02M 2.9B 42.6M 288M 113M 1.45B 114M 111M 4.83B	EV / Sales 2026 *	8.44x	EV / Sales 2027 *	2.43x
Free-Float	97.31%	Yield 2026 *	-	Yield 2027 *	-

07-22	Valbiotis Publishes Results of Reverse-It Clinical Study Evaluating Totum 63 in Nature Communications	CI
06-29	Valbiotis Raises EUR10 Million for Commercial Development, Working Capital	MT
06-26	Valbiotis successfully completes a €10.2m capital increase
06-08	Valbiotis Secures Exclusive Distributor in Qatar	MT
06-08	Valbiotis and Al Danah Medical Company Signs Exclusive Distribution Agreement for Valbiotispro Range in Qatar	CI
06-08	Valbiotis strengthens Middle East presence through Qatar partnership
05-27	Valbiotis SA Announces EU Member States Vote in Favor of Regulation Banning Monacolins From Red Yeast Rice	CI
05-12	Valbiotis shares surge on Asian expansion plans
05-12	Atos, Fnac Darty, Chargeurs... stocks to watch today in Paris
05-11	Valbiotis and Aika Form Joint Venture and Establish Subsidiary in Singapore	CI
05-11	Pluxee, Lacroix, Valbiotis... stocks to watch tomorrow in Paris
05-11	Valbiotis continues Asian expansion with the establishment of a Singapore subsidiary
05-11	Valbiotis announces creation by Chinese JV of subsidiary in Singapore	RE

07-27	VALBIOTIS SA: Cardiovascular Prevention Act: A response to a major public health challenge A milestone fully aligned with Valbiotis’ mission	EQ
07-22	VALBIOTIS SA: Results of the REVERSE-IT clinical study published in Nature Communications, a major international scientific recognition for the ingredient Totum•63	EQ
06-26	VALBIOTIS SA: Valbiotis announces the success of its capital increase of €10.2M	EQ
06-08	VALBIOTIS SA: Valbiotis announces the launch of a capital increase with maintained PSR in the amount of €10.2M secured by commitments amounting to 76.6%	EQ
06-08	VALBIOTIS SA: Valbiotis announces the signing of an exclusive distribution agreement in Qatar, a new milestone in the brand’s expansion in the Middle East	EQ

1 day	-0.47%
1 week	+5.16%
Current month	+11.17%
1 month	+7.27%
3 months	-22.32%
6 months	-19.25%
Current year	+23.34%

1 week	0.81	0.91
1 month	0.74	0.91
Current year	0.65	1.3
1 year	0.54	1.3
3 years	0.54	7.5
5 years	0.54	7.5
10 years	0.54	10.65

Valbiotis Stock

Stocks

ALVAL

FR0013254851

Biotechnology & Medical Research

Valuation: Valbiotis

Chart: Valbiotis

Latest news : Valbiotis

Analysts' recommendations: Valbiotis

Press Releases: Valbiotis

News in other languages: Valbiotis

Quotes and Performance

Course Extremes

Managers and Directors: Valbiotis

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Annual profits - Rate of surprise

Date	Insider	Type	Main position	Quantity	% Market Cap.
1/28/22	Jocelyn Pineau	Others	Founder	42,480	0.4364%
1/28/22	Jocelyn Pineau	Fiscal year	Founder	2,095	0.0215%
7/10/21	Pascal Sirvent	Fiscal year	Chief Technology Officer	2,000	0.0206%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VALBIOTIS	-0.47%	+5.16%	-4.89%	-80.89%	23.56M
WUXI APPTEC CO., LTD.	+4.80%	+7.80%	+70.64%	+114.21%	70.07B
ARGENX SE	+17.12%	+11.50%	+54.42%	+87.30%	52.87B
INSMED INCORPORATED	+3.70%	-4.77%	+0.41%	+484.07%	27.02B
WUXI BIOLOGICS (CAYMAN) INC.	+2.26%	+0.65%	+49.19%	+10.30%	23.61B
BIONTECH SE	-1.60%	-1.29%	-19.31%	-19.10%	23.38B
PHARMAESSENTIA CORPORATION	-6.00%	+13.71%	+244.39%	+443.26%	19.43B
GENMAB A/S	+3.80%	+5.25%	+40.50%	-16.41%	18.75B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.38%	-3.15%	+20.39%	+589.77%	15.85B
EXELIXIS, INC.	+2.11%	-1.21%	+36.57%	+149.14%	12.7B
Average	+2.61%	-0.76%	+49.23%	+176.16%	26.37B
Weighted average by Cap.	+5.10%	-0.92%	+56.29%	+170.80%

	2026 *	2027 *
Net sales	3.1M 3.59M 2.91M 2.65M 4.98M 343M 5.05M 34.09M 13.36M 172M 13.48M 13.19M 572M	12.8M 14.83M 12.01M 10.94M 20.57M 1.42B 20.85M 141M 55.16M 710M 55.67M 54.46M 2.36B
Net income	-8.2M -9.5M -7.69M -7.01M -13.17M -908M -13.36M -90.18M -35.34M -455M -35.66M -34.89M -1.51B	-2.8M -3.24M -2.63M -2.39M -4.5M -310M -4.56M -30.79M -12.07M -155M -12.18M -11.91M -517M
Net Debt	5.9M 6.83M 5.54M 5.04M 9.48M 653M 9.61M 64.89M 25.43M 327M 25.66M 25.1M 1.09B	10.9M 12.63M 10.23M 9.31M 17.51M 1.21B 17.76M 120M 46.97M 605M 47.4M 46.38M 2.01B